Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cortexyme, Inc. - Common Stock (NQ:CRTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cortexyme, Inc. - Common Stock

< Previous 1 2 Next >
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
From Cortexyme, Inc.
Via Business Wire
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
From Cortexyme, Inc.
Via Business Wire
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
From Cortexyme, Inc.
Via Business Wire
Cortexyme Appoints June Bray to its Board of Directors
From Cortexyme, Inc.
Via Business Wire
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
From Cortexyme, Inc.
Via Business Wire
Cortexyme Successfully Completes Acquisition of Novosteo
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
From Cortexyme, Inc.
Via Business Wire
Cortexyme Announces Agreement to Acquire Novosteo
From Cortexyme, Inc.
Via Business Wire
NASDAQ:CRTX Investor Alert: Investigation over Potential Wrongdoing at Cortexyme, Inc.
San Diego, CA -- (SBWIRE) -- 04/29/2022 -- Certain directors of Cortexyme, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX
From The Rosen Law Firm, P.A.
Via Business Wire
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
From Cortexyme, Inc.
Via Business Wire
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Present New GAIN Trial Data at AD/PD 2022
From Cortexyme, Inc.
Via Business Wire
CORTEXYME ALERT: Bragar Eagel & Squire, P.C. is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ:CRTX Shareholder Notice: Investigation over Potential Securities Laws Violations by Cortexyme, Inc.
San Diego, CA -- (SBWIRE) -- 02/24/2022 -- Cortexyme, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
CORTEXYME ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Business Wire
Investigation Notice: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Investigation Alert: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles - (NewMediaWire) - February 16, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cortexyme,... 
Via NewMediaWire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – CRTX
From Rosen Law Firm
Via Business Wire
Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones
From Cortexyme, Inc.
Via Business Wire
Cortexyme Announces Change in Executive Leadership Team
From Cortexyme, Inc.
Via Business Wire
Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th
From Cortexyme, Inc.
Via Business Wire
Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
From Cortexyme, Inc.
Via Business Wire
Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021
From Cortexyme, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.